Gene · 54888
Papers1,406
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,406
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RNA-Binding Peptide Influences Epitranscriptomic Regulation by Preferentially Binding to Unmodified RNAs Targeted by NSUN2. | Biomolecules | 2026 | 42793119 | PubTator, text mining | PubMed |
| NSUN2-mediated m5C modification of HIV-1 RNA enables evasion of RIG‑I‑dependent innate immunity. | PLoS Pathog | 2026 | 42789514 | PubTator, text mining | PubMed |
| RNA derived from cancer cells as a scaffold for amyloid-β25-35 aggregation: the effect of RNA methylation and rRNA status. | Int J Biol Macromol | 2026 | 42785408 | PubTator, text mining | PubMed |
| NSUN2 promotes glycolysis and stemness of retinoblastoma cells by m5C modification of PFKFB3. | Tissue Cell | 2026 | 42753463 | PubTator, text mining | PubMed |
| 5-Azacytosine induces cytotoxicity via 5-methylcytosine depletion on chromatin-associated RNA in leukemia. | Mol Cell | 2026 | 42743920 | PubTator, text mining | PubMed |
| Tumor-intrinsic NSUN2 orchestrates immunosuppression in lung adenocarcinoma via the m5C-HDAC8-CCL5 axis. | Exp Hematol Oncol | 2026 | 42706582 | PubTator, text mining | PubMed |
| Cellular signal-responsive m5C editing by an inducible split CRISPR platform. | RNA | 2026 | 42680563 | PubTator, text mining | PubMed |
| Metabolic Reprogramming of NSUN2-Mediated m5C Modification Promotes the Progression of Hepatocellular Carcinoma by Restricting Natural Killer Cell-Mediated Cytotoxicity. | Cancer Commun (Lond) | 2026 | 42676762 | PubTator, text mining | PubMed |
| NSUN2 Promotes Cancer Immune Evasion via Its Moonlighting Function Acting on Metabolic Reprogramming. | Cancer Commun (Lond) | 2026 | 42620795 | PubTator, text mining | PubMed |
| A m6A/m1A/m5C-related eight-gene signature predicts prognosis and correlates with immune microenvironment in pediatric acute myeloid leukemia. | Transl Pediatr | 2026 | 42591630 | PubTator, text mining | PubMed |
| m5C Methylation of mRNA: Still More Questions Than Answers. | Cells | 2026 | 42587746 | PubTator, text mining | PubMed |
| Integrating Parallel-Bias Metadynamics-Metainference and Relaxation Dispersion NMR to Resolve Hidden Conformational States Driving Toxin-Channel Recognition. | J Am Chem Soc | 2026 | 42584632 | PubTator, text mining | PubMed |
| NSUN2 suppresses ferroptosis via the KLF4/GPX4 axis to preserve stem cells and tissues. | Redox Biol | 2026 | 42551125 | PubTator, text mining | PubMed |
| NSUN2 regulates PARP9 progression through m5C modification to mediate breast cancer progression. | Cell Div | 2026 | 42472828 | PubTator, text mining | PubMed |
| NSUN2-Mediated m5C Methylation in Human Disease: Mechanism and Therapeutic Implications. | Int J Gen Med | 2026 | 42454353 | PubTator, text mining | PubMed |
| Identification of Candidate Biomarkers Associated with Mitochondrial Dysfunction and SUMOylation in Heart Failure Based on Bioinformatics Approaches. | J Vis Exp | 2026 | 42441434 | PubTator, text mining | PubMed |
| YBX1 Promotes Malignant Progression of HNSCC via Stabilizing NSUN2-m5C Modified ATF4 mRNA. | Cancer Sci | 2026 | 42429160 | PubTator, text mining | PubMed |
| NSUN2 integrates glucose and one‑carbon metabolism upstream of Rag GTPase-dependent mTORC1 signaling. | Cell Signal | 2026 | 42425210 | PubTator, text mining | PubMed |
| NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis. | Respir Res | 2026 | 42399962 | PubTator, text mining | PubMed |
| Cerium Nanoparticle-Mediated Inhibition of the NSUN2/m5C Axis Suppresses Synovial Aggression in Rheumatoid Arthritis. | Adv Sci (Weinh) | 2026 | 42397077 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54888/papers